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          Bruk av antikolinerge antiparkinsonmedikamenter i Norge. 
                Epidemiologi, toksikologi og kliniske konsekvenser. 
                                            Pål Gjerden 
          På slutten av 1990-tallet oppdaget vi at legemidlet orfenadrin, markedsført i Norge 
under navnet Disipal©, foruroligende ofte forårsaket forgiftningsdødsfall. Orfenadrin 
tilhører en gammel og lite påaktet gruppe medikamenter, antikolinerge 
antiparkinsonmedikamenter, som opprinnelig ble brukt i behandling av Parkinsons 
sykdom. I to artikler i Tidsskrift for den norske legeforening advarte vi mot bruken av 
dette medikamentet. Etter advarselen gikk salget ned i Norge. Det var ingen tilsvarende 
reduksjon i Sverige og Danmark, noe som kan tyde på at advarselen i fagtidsskriftet 
hadde effekt på legers forskrivningspraksis. Orfenadrin ble trukket fra det skandinaviske 
markedet i 2005, men er fortsatt tilgjengelig i store deler av verden. 
          Ved hjelp av data fra Reseptregisteret har vi i ettertid vist at antikolinerge 
antiparkinsonmedikamenter nå i all hovedsak brukes sammen med antipsykotiske 
legemidler, og at bruken av antikolinerge midler kan indikere forekomst av en spesiell 
type alvorlige bivirkninger forårsaket av slike antipsykotiske medisiner. Vi brukte denne 
sammenhengen for å undersøke hvilke spesifikke antipsykotiske medisiner som var 
tryggest å bruke. Denne tilnærmingsmåten for å vurdere legemiddelsikkerhet er på 
mange måter ny. Det er blitt påstått at nyere antipsykotika gir færre bivirkninger enn 
eldre. Vi fant stor variasjon mellom de ulike antipsykotika, men ingen systematiske 
forskjeller mellom eldre og yngre midler mht. sambruk med antikolinerge 
antiparkinsonmidler. Påstanden om at nyere antipsykotika har en generelt bedret 
bivirkningsprofil synes primært å dreie seg om markedsføring. 
          Vi ønsket også å vurdere risiko for bivirkninger ved å se på hvilke medikamenter 
som ble foretrukket over tid. Vi antok at langtidsbruk av medisiner betyr at pasientene er 
fornøyde, enten fordi de opplever god virkning eller lite bivirkninger eller begge deler. 
Klozapin (Leponex©) og zuclopentixol (Cisordinol©) var de antipsykotiske medisinene 
som var hyppigst i kontinuerlig bruk over tre år. Vi fant en høy grad av sambruk av 
zuclopentixol og antikolinerge medikamenter. En forklaring kan være at effekten av 
zuclopentixol ble oppfattet som så god at det veide opp for bivirkningene. En slik måte å 
vurdere medikamenteffekt på har heller ikke vært gjort tidligere. Et overraskende og 
bekymringsfullt bifunn var at bruk av haloperidol (Haldol©) var assosiert med betydelig 
overdødelighet. 
Dr. philos., NTNU, Det medisinske fakultet, Institutt for laboratoriemedisin, barne- og 
kvinnesykdommer, 251110. Veiledere: Lars Slørdal og Jørgen G. Bramness. 
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1. Overview 
 
1.1 Summary 
 
This thesis is based on two fundamental questions: Which patients are 
currently using anticholinergic antiparkinson drugs? Does it matter which 
anticholinergic antiparkinson drug they are using? These questions were 
further investigated, using a variety of methods, as follows: 
 
Are anticholinergic antiparkinson agents predominantly used to treat 
Parkinson’s disease or antipsychotic induced extrapyramidal side-effects 
(EPS)? 
 
Is there a high risk of abuse of anticholinergic antiparkinson agents? 
 
Can alleged differences in receptor binding profiles of typical first- 
(FGA) and atypical second (SGA) -generation antipsychotic agents 
predict concomitant use of anticholinergic agents?  
 
Can long-term co-prescription of anticholinergic antiparkinson agents 
shed some light on the efficacy of antipsychotic agents? 
 
Does the literature indicate differences in toxicity and fatality rates of 
anticholinergic antiparkinson agents? Does an autopsy material indicate 
differences between anticholinergic agents regarding toxicity and fatality 
risk?  
 
Are warnings in a medical journal against the use of the most toxic 
anticholinergic agent enough to reduce its use?  
 
Can patients stop using anticholinergic agents without further remedies? 
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The thesis has the following conclusions: 
 
The overwhelming majority of anticholinergic users were patients 
concomitantly using antipsychotic agents, presumably for the alleviation 
of antipsychotic induced EPS. The use of anticholinergics was not 
particularly skewed and we could not find any other indication of abuse, 
indicating that concomitant use of anticholinergics can be a proxy for the 
liability of specific antipsychotic agents to cause EPS. 
 
For patients using only one antipsychotic agent, the concurrent use of 
anticholinergics varied between 0.4% and 26.0%, but largely 
independently of the distinction between typical and atypical 
antipsychotics. High D2-receptor antagonism and a high 5-HT2A/D2-
receptor-affinity ratio coincided with the use of anticholinergics. 
 
Clozapine and zuclopentixol demonstrated the highest level of 
prescription persistence in a three-year period. The high prevalence of 
concomitant use of anticholinergics and zuclopentixol may indicate that 
the latter was considered efficacious enough to outweigh its probable 
side-effects. Haloperidol was associated with a mortality three times that 
of any other antipsychotic agent in the study.  
 
Orphenadrine is by far the most toxic anticholinergic antiparkinson agent 
with a high mortality risk. Warnings in a medical journal against the use 
of a toxic drug can have an impact on prescription patterns.  
 
At least one-third of the patients using anticholinergic antiparkinson 
agents do not need them. 
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2 General introduction 
 
2.1 Anticholinergic agents 
 
Acetylcholine acts at two different classes of cholinergic receptors, 
nicotinic ligand-gated ion channels and G-protein-coupled muscarinic 
receptors. Both confer a wide range of effects in the periphery as well as 
the central nervous system (1). Acetylcholinesterase inhibitors, used in 
the treatment of Alzheimer’s disease, are the best known modulators of 
nicotinic receptor function. The class of drugs called anticholinergic 
agents acts as competitive antagonists at muscarinic receptors only and 
should more precisely be named antimuscarinic agents. However, the 
term anticholinergic agents is the term used in the official nomenclature 
of World Health Organization (WHO) and is thus adopted throughout 
this thesis (2).  
 
Anticholinergic agents have been known in many cultures for thousands 
of years. The prototype of the muscarinic antagonists, atropine, is 
naturally occurring in Atropa belladonna and several other members of 
the Solanaceae genus of plants (1). These naturally occurring 
anticholinergic agents have been used for a variety of reasons through 
history. The term belladonna refers to the beautiful women of Italy who 
considered the mydriatic effect aesthetically desirable.  
 
The first man-made anticholinergic agents were introduced in 1946, 
trihexyphenidyl/benzhexol and biperiden followed by procyclidine, 
benztropine and, lastly, orphenadrine in 1951 (3-10). The effect 
conferred by these agents on Parkinson’s disease and neuroleptic-induced 
parkinsonism is assumed to be mediated by reducing the imbalance 
between cholinergic and dopaminergic activity in nigrostriatal neurons. 
Orphenadrine confers a wide range of effects in addition to muscarinic 
blockade (11).  
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2.2 Parkinson’s disease 
 
James Parkinson published “An essay on the shaking palsy” in 1817. 
Although incomplete, this was the first description of a clinical condition 
that Jean-Martin Charcot half a century later named “maladie de 
Parkinson”. The medically correct term paralysis agitans has never been 
as popular in clinical use as Parkinson’s disease. First thought to be a 
nosological entity, its heterogeneity makes it more correct to use the term 
Parkinson’s syndrome instead of Parkinson’s disease. The classic 
symptoms tremor, rigidity and bradykinesia are assumed to find their 
primary neurological substrate in the loss of dopaminergic neurons in the 
nigrostriatal pathway, although the pathogenetic process behind this 
deficiency may vary (12-14).  
 
The first medicinal intervention was the administration of extract from 
Atropa belladonna in 1867. From the late 1940s onwards synthesized 
anticholinergic agents came into extensive use. Until the development of 
L-dopa in the early 1960s, they were the mainstay of Parkinson’s disease 
treatment (12). The medical treatment of Parkinsons’ disease has made 
further progress since then (15). 
 
 
              2.3. Parkinsonism 
 
Before antipsychotic agents came into use the terms Parkinson’s disease 
and parkinsonism were used synonymously. Following the introduction 
of chlorpromazine in 1952, the propensity of antipsychotic agents to 
induce parkinsonian symptoms was recognized and eventually named 
parkinsonism (drug-induced parkinsonism), as a entity different from, but 
mimicking, Parkinson’s disease (idiopathic parkinsonism). At first it was 
regarded as a clinical manifestation of the desirable pharmacological 
action and it took many years before it was considered an undesirable 
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adverse effect. Sedation, anticholinergic effects and hypotension were the 
acknowledged side-effects of the early low-potency agents and it was not 
until the introduction of the more potent and specific D2 receptor 
antagonists, culminating with the synthesis of haloperidol in 1958, that 
parkinsonian adverse effects were recognized as a major problem. 
Eventually, drug-induced parkinsonism came to be considered the most 
serious hindrance for the use of antipsychotic agents and a diminished 
liability to promote parkinsonism became the main argument in the 
endeavour to define a new generation of antipsychotics (16).  
 
The first - some would say the only - atypical antipsychotic agent was 
clozapine, demonstrating virtually no parkinsonian side-effects. 
Clozapine was marketed from the early 1970s, withdrawn because of its 
significant haematological toxicity and reintroduced in the 1990s because 
of its unique efficacy. In a quest to replicate the efficacy and lack of 
abnormal motor symptoms demonstrated by clozapine, avoiding its 
haematological side-effects, a number of novel atypical antipsychotic 
agents have been synthesized in the last decade (17).  
 
Abnormal motor symptoms caused by antipsychotic agents are usually 
named extrapyramidal side-effects (EPS) and most often sub-divided into 
acute dystonia, parkinsonism and akathisia, thus defining tardive 
dyskinesia as an entity of its own. Some authors, however, include 
tardive dyskinesia as an EPS. In clinical practice, the terms EPS and 
parkinsonism are often used as synonyms, while akathisia and tardive 
dyskinesa are described as separate entities. Acute dystonia, being an 
acute condition, is mostly confined to hospitalized patients and should 
have little bearing on any of the papers that constitute this thesis.  
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2.4 Efficacy and effectiveness 
 
The terms efficacy and effectiveness are frequently used in the medical 
literature. Seemingly similar in meaning, they express different concepts. 
The term efficacy refers to the question if a treatment works under ideal 
condition, the randomized controlled trial (RCT) being the archetypal 
example. The term effectiveness refers to the question if the treatment 
works in everyday life. If the treatment does more harm than good to the 
patient, possibly because of bothersome side-effects, the treatment might 
be rejected and is thus ineffective although it may be efficacious (18). 
There has been a growing difficulty in translating the results of RCTs 
into clinical practice concerning the clinical usefulness of old and newer 
antipsychotic agents (19). 
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3 Introduction to the present study 
 
3.1. Epidemiology 
 
The use of anticholinergic agents in Parkinson’s disease has been in 
decline, at least in the industrialized countries of the world, but its use is 
not altogether obsolete (20). The low cost incurred by its use is probably 
the reason for the not insignificant use of these drugs against Parkinson’s 
disease worldwide. In Norway, the use of anticholinergic agents was 
assumed to be largely confined to treating antipsychotic induced side-
effects. This assumption had, however, not been formally investigated. 
Paper 1 delineates the prevalence and indication of use of anticholinergic 
antiparkinson drugs in Norway and investigates possible abuse of these 
drugs. The users of anticholinergic antiparkinson drugs are further 
scrutinized in Paper 2, assessing the concomitant use of anticholinergic 
and antipsychotic agents. 
 
3.1.1. Clinical implications 
 
The prevalence of antipsychotic induced EPS has been much debated. 
Second-generation antipsychotic agents (SGAs) have been claimed to 
confer a much lower risk of inducing EPS than first-generation 
antipsychotics (FGAs). This notion has been challenged in the last few 
years, in the wake of two large clinical studies that failed to demonstrate 
any difference between FGAs and SGAs in this respect (21, 22). A 
confounding factor is that almost all studies of drug-induced EPS have 
been carried out with schizophrenic patients, a group of patients with an 
inherent tendency of developing both parkinsonism and tardive 
dyskinesias even in the absence of antipsychotic agents.  
 
We found that the overwhelming majority of anticholinergic 
antiparkinson drugs were used concomitantly with antipsychotic agents, 
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presumably for the amelioration of antipsychotic induced EPS. We could 
not find indications of a skewed use of anticholinergic drugs. 
Consequently we assumed that concomitant use of anticholinergics might 
reflect perceived EPS and that concomitant use of anticholinergics could 
be used as a proxy for antipsychotic induced EPS. In particular we 
investigated potential differences between FGAs and SGAs. Paper 2 
focuses on differences in the liability of antipsychotic agents to cause 
EPS and explores some pharmacodynamic differences between FGAs 
and SGAs. 
 
If doctors and patients stick to a single antipsychotic agent for years, one 
might assume that both efficacy and lack of side-effects is considered 
satisfactory and that the drug has demonstrated effectiveness. In addition 
to assessing prescription persistence as a proxy for the real-life 
effectiveness of antipsychotic agents, Paper 3 compares concomitant 
prescription of anticholinergic antiparkinson agents and mortality as 
indicators of safety of antipsychotic agents. In addition, long-term 
concomitant prescription of antipsychotic and anticholinergic agents is 
used in an indirect evaluation of the efficacy of some of the antipsychotic 
agents in the study. 
 
3.2. Toxicology 
 
Anticholinergic antiparkinson agents constitute a very old class of drugs. 
They were introduced at a time when preclinical trials were less 
comprehensive than today and pharmacokinetics and metabolism were 
scantily described before marketing. This is still the case. Scattered case-
reports have been published but, to our knowledge, no review that deals 
comprehensively with the toxicology of anticholinergic antiparkinson 
drugs. Standard psychiatric textbooks do not differentiate between the 
various anticholinergics. Paper 4 is a review of the clinical pharmacology 
of the three anticholinergic antiparkinson drugs marketed in Norway at 
the time of the study, with emphasis on acute toxicity. Paper 5 is a study 
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of a series of fatalities caused by anticholinergic antiparkinson drugs in 
Norway in an 11-year period.  
 
3.2.1. Clinical implications 
 
The toxicology of anticholinergic antiparkinson agents is not the same. 
The results from Papers 4 and 5 indicate that orphenadrine stands out 
from the rest, being responsible for a disproportionately large number of 
overdose deaths. Consequently, in Paper 5 we warned against the use of 
orphenadrine. Journal reading is probably the most popular form of 
continuous medical education but it is difficult to demonstrate an effect 
on doctors’ professional behaviour (23, 24). Studies reporting positive 
effect of passive educational initiatives are very scarce (25). Paper 6 
examines whether warnings in a medical journal against the use of 
orphenadrine had any effect on the sales of this compound in Norway. 
 
Eventually, orphenadrine was withdrawn from the Scandinavian market. 
Paper 7 focuses on the consequences for the patients when they stopped 
using orphenadrine, regarding the use of anticholinergic and 
antipsychotic agents. 
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4   Research questions 
 
This work elaborates on two basic questions: Which patients are 
presently using anticholinergic antiparkinson drugs? Does it matter 
which anticholinergic antiparkinson drug they are using?  
 
The respective answers to these questions consequently led to the 
following research questions that this thesis aims to answer: 
 
1. It is assumed that the use of anticholinergic antiparkinson agents 
today is mainly confined to the alleviation of antipsychotic 
induced EPS. Is this assumption correct? This question is dealt 
with in Paper 1. 
2. The reported risk of abuse of anticholinergic antiparkinson agents 
varies considerably in the literature. Is there a high risk of abuse 
of these drugs? This question is also dealt with in Paper 1. 
3. The reported prevalence of antipsychotic induced EPS differs 
significantly in the literature. In particular, newer studies have 
questioned the alleged diminished liability of the atypical second-
generation antipsychotics to induce EPS. Is the prevalence of 
drug-induced EPS the same for all antipsychotic agents? Is there a 
difference between FGAs and SGAs in this aspect? Can alleged 
differences in receptor binding profiles of FGAs and SGAs 
predict concomitant use of anticholinergic agents? Paper 2 deals 
with these questions. 
4. Paper 3 deals with prescription persistence and safety, including 
mortality, associated with antipsychotic medication. Are there any 
differences between the various antipsychotics? Can concomitant 
use of anticholinergic agents help differentiate efficacy from 
perceived side-effects as possible reasons for long-term 
prescription persistence of antipsychotic agents?  
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5. What does the literature tell us about the toxicity and fatality risk 
of anticholinergic antiparkinson drugs? Do these drugs differ 
from each other in this aspect? Paper 4 deals with this question. 
6. Are there differences in toxicity between anticholinergic 
antiparkinson agents in a Norwegian autopsy material? This 
question is dealt with in Paper 5. 
7. Papers 4 and 5 delineate orphenadrine as a drug quite different 
from the rest of the anticholinergic antiparkinson agents, carrying 
a significantly higher risk of death than any other anticholinergic 
agent. Will a warning against the use of orphenadrine result in a 
decline of the use of this drug? Paper 6 deals with this question. 
8. Can patients stop using orphenadrine or other anticholinergic 
antiparkinson drugs when they have to, without reducing 
antipsychotic dosage, switching antipsychotic agent or replacing 
one anticholinergic agent with another? Paper 7 deals with these 
questions. 
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5 Material and methods 
 
5.1 Design 
 
Papers 1, 2, 3 and 7 are pharmacoepidemiological studies. Paper 4 is a 
literature review while Paper 5 is a retrospective study of a series of 
autopsy cases. Paper 6 is a naturalistic study with case-control elements. 
 
5.2 Material 
 
Papers 1, 2, 3 and 7 are based on the Norwegian Prescription Database 
(NorPD) which covers sales of drugs to the entire Norwegian outpatient 
population from 2004. Paper 4 is based on an extensive literature search 
in various databases. The basis for Paper 5 is autopsy samples received at 
the National Institute of Forensic Toxicology during the years 1986 – 
1996. Paper 6 compares drug sales to the entire Norwegian, Swedish and 
Danish outpatient population as reported to the national health 
authorities.  
  
5.3 Methods 
 
Papers 1, 2, 3 and 7 uses one-year prevalence as the basic measure and 
collects standard pharmacoepidemiological data from NorPD for this 
period of time. In addition to standard epidemiological calculations, we 
also found Lorenz curves and Gini coefficients useful in the evaluation of 
possible drug abuse in Paper 1. Paper 2 extracts antipsychotic receptor 
profiles from a previously published external source. Paper 6 uses 
standard epidemiological data and calculations. 
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5.4 Statistics 
 
The main statistical methods used in the present analyses are simple 
frequency analyses performed in SPSS 15.0 using Pearson’s chi-square 
(²) test for the assessment of significance. In addition, Spearman’s rank 
correlation coefficient () was used in Paper 2 and binary logistic 
regression analyses with odds ratios were performed in Paper 3. 
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6 Results   
 
6.1 Paper 1. 
 
The use and potential abuse of anticholinergic antiparkinson drugs 
in Norway. A pharmacoepidemiological study. 
 
Pål Gjerden, Jørgen G. Bramness, Lars Slørdal 
 
British Journal of Clinical Pharmacology 2008; 67(2): 228-233 
 
The use of anticholinergic antiparkinson drugs is assumed to have shifted 
from the therapy of Parkinson’s disease to the amelioration of 
extrapyramidal adverse effects induced by antipsychotic drugs. There is a 
considerably body of data suggesting that anticholinergic antiparkinson 
drugs have a potential for abuse. The aim was to investigate the use and 
potential abuse of this class of drugs in Norway. 
 
Data were drawn from the Norwegian Prescription Database on sales to a 
total of 73 964 patients in 2004 of biperiden and orphenadrine, and use in 
patients with Parkinson’s disease or in patients who were also prescribed 
antipsychotic agents. Possible abuse of these drugs was assessed by the 
level of use, skewedness of use, indications of drug-seeking behaviour 
and concomitant use of benzodiazepine tranquillizers, a group of drugs 
with a recognized potential for abuse. 
 
Patients using antipsychotic medication accounted for 94% of the use of 
anticholinergics, compared with 4.3% with Parkinsons’disease. We 
found indications of abuse of benzodiazepine tranquillizers among 
patients using antipsychotics, but there were no clear indications of abuse 
of anticholinergics, even among patients who were strongly suspected of 
abuse of bezodiazepines. 
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Anticholinergic antiparkinson drugs were primarily used by patients with 
psychotic illnesses. These patients have a very high prevalence of legal 
and illegal drug abuse, but the risk of abuse of anticholinergic 
antiparkinson drugs seemed small. 
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6.2 Paper 2 
 
Association between the use of anticholinergic antiparkinson drugs 
and safety and receptor drug-binding profiles of antipsychotic agents 
 
Pål Gjerden, Lars Slørdal, Jørgen G. Bramness 
 
European Journal of Clinical Pharmacology 2009; 65(12): 1229-1235 
 
The use of anticholinergic antiparkinson drugs is almost exclusively 
confined to treating antipsychotic-induced extrapyramidal side-effects 
(EPS). We investigated the prevalence of concomitant prescription of 
anticholinergics as a proxy for antipsychotic-induced EPS and compared 
variance in prevalence with differences in the assumed mechanisms of 
action of antipsychotics on central nervous system (CNS) transmitter 
systems (i.e., receptor drug-binding profiles). We paid special attention to 
potential differences between typical and atypical antipsychotics. 
 
Data were drawn from the Norwegian Prescription Database on sales of 
antipsychotic and anticholinergic antiparkinson drugs to a total of 57 130 
outpatients in 2004. We assessed concomitant dispensations of 
antipsychotic and anticholinergic drugs and correlated the prevalence of 
concomitantly prescribed anticholinergics to previously assessed 
receptor-binding profiles of antipsychotics. 
 
The concurrent use of anticholinergics varied between 0.4% and 26.0% 
for patients using a single antipsychotic agent. The prevalence of 
anticholinergic comedication was more than twice as high in patients 
using two or more antipsychotic drugs. Four typical antipsychotics 
(fluphenazine, zuclopentixol, haloperidol and perphenazine) were 
associated with higher concomitant use of anticholinergics than the rest. 
For the remaining 14 antipsychotic agents, the difference between typical 
and atypical antipsychotics was neither pronounced nor systematic. A 
 24
high degree of D2-receptor antagonism and a high 5-HT2A/D2-receptor-
affinity ratio coincided with the use of anticholinergics. 
 
The liability of antipsychotic drugs to cause EPS seemed to vary 
considerably and largely independently of the distinction between typical 
and atypical antipsychotics. 
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6.3 Paper 3. 
 
Prescription persistence and safety of antipsychotic medication: a 
national registry-based three-year follow-up 
 
Pål Gjerden, Lars Slørdal, Jørgen G. Bramness 
 
European Journal of Clinical Pharmacology 2010; 66: 911-917 
 
Long-term persistence of use, lack of co-prescribed anticholinergic 
antiparkinson drugs and low mortality may indicate effectiveness and 
safety of antipsychotic drugs. We aimed to assess three-year prescription 
persistence, concomitant use of anticholinergic antiparkinson agents and 
mortality related to the use of all antipsychotic agents available in 
Norway. 
 
Data were drawn from the Norwegian Prescription Database on the sales 
of antipsychotic and anticholinergic antiparkinson agents in 2004 to a 
total of 52 427 patients. The primary study group was a subgroup of 
34 494 patients who were prescribed only one antipsychotic agent in 
2004. The patients were re-investigated in 2007. For each of the 13 
antipsychotic agents studied, assumed prescription persistence was 
assessed in light of use of anticholinergic antiparkinson agents in 2004 
and casualty rates were noted. 
 
The highest persistence was demonstrated by zuclopenthixol (69.8%) and 
clozapine (88.4%). Zuclopenthixol was often co-prescribed with 
anticholinergics (22.2%), in contrast to clozapine (3.6%). Ziprasidone 
was associated with a low mortality (OR=0.08), while chlorprotixene and 
haloperidol were associated with a high mortality (OR=1.34 and 3.97, 
respectively) compared to levomepromazine. 
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Clozapine demonstrated a high degree of continuity of prescription and a 
low level of concomitant use of anticholinergics. Zuclopenthixol also 
demonstrated a high degree of continuity of prescription, despite a 
considerable degree of co-prescribed anticholinergics. We did not find 
that any other antipsychotic than ziprasidone was associated with a low 
mortality. The use of haloperidol seemed to confer a mortality risk three 
times that of any of the other antipsychotic agents included. 
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6.4 Paper 4. 
 
The clinical pharmacology of anticholinergic antiparkinson drugs: a 
review with emphasis on acute toxicity 
 
Pål Gjerden, Lars Slørdal 
 
Tidsskrift for Den norske lægeforening 1998; 118: 53-55 
 
Anticholinergic antiparkinson drugs are primarily used to ameliorate 
extrapyramidal side-effects induced by neuroleptic agents. In 1998 
orphenadrine dominated quantitatively among these drugs in Norway, 
presumably because it was assumed to carry a lower risk of abuse. 
 
There are numerous reports of deaths following orphenadrine overdoses. 
Orphenadrine has complex pharmacokinetic properties and a narrow 
therapeutic index. After an overdose, it confers toxic effects of rapid 
onset to several organ systems. No specific and effective therapy for 
orphenadrine intoxications has been established. For the two other drugs 
in this class which were marketed in Norway at this time, biperiden and 
benztropine, toxicity is mainly connected to their anticholinergic 
properties. Notably, no reports of lethalities after overdoses of biperiden 
seem to be available. A small number of accounts of deaths following 
benztropine intoxications have been published. Neither of these two 
agents, and benztropine in particular, has been subjected to 
comprehensive pharmacokinetic evaluations. 
 
The relatively extensive use of orphenadrine should be discouraged. 
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6.5 Paper 5. 
 
Fatalities caused by anticholinergic antiparkinson drugs: a 
retrospective study of a series of Norwegian cases 
 
Pål Gjerden, Karen Sofie Engelstad, Grete Pettersen, Lars Slørdal 
 
Tidsskrift for Den norske lægeforening 1998; 118: 42-44 
 
All autopsy samples received at the National Institute of Forensic 
Toxicology during the years 1986-1996 which contained anticholinergic 
antiparkinson drugs were reviewed. Of a total of 69 cases, orphenadrine 
was present in 57 (83%), biperiden in 8 (12%), procyclidine in 3 (4%) 
and trihexyphenidyl/benzhexol in 1 (1%) of the subjects. The measured 
concentrations were assessed in light of previously published data. Of 21 
cases where causality between drug ingestion and death was classified as 
either highly probable (18/21) or possible (3/21), all subjects tested 
positive for orphenadrine. In the autopsy samples from these patients, 
orphenadrine concentrations in the 4.5 – 600 mol/l range (mean 62.5 
mol/l, SD 126.5 mol/l) were determined. Because of a low national 
autopsy rate, there is reason to believe that the actual numbers of drug-
related deaths in this period may have been significantly higher.  
 
It is concluded that orphenadrine is responsible for a disproportionately 
high number of overdose deaths. 
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6.6 Paper 6. 
 
Effect of warnings in a medical journal on the use of orphenadrine 
 
Pål Gjerden, Jørgen G. Bramness, Lars Slørdal 
 
Journal of Evaluation in Clinical Practice 2008; 14: 615-617 
 
The effect of journal reading on doctors’ professional behaviour has not 
been extensively studied. We have tried to assess the impact of a warning 
against the use of orphenadrine published in an extensively circulated 
Norwegian medical journal. 
 
Based on evidence of excessive toxicity we published a warning against 
the use of orphenadrine in the Journal of the Norwegian Medical 
Association in 1998. There were no such initiatives in neighbouring 
Scandinavian countries. Yearly sales data for orphenadrine in Norway 
were compared to sales data from Sweden and Denmark before and after 
this warning. 
 
Sales data showed a steeper decline in the prescription of orphenadrine in 
Norway compared to Sweden and Denmark from the time of intervention 
in 1998 until the drug was withdrawn from the Scandinavian market in 
2005. 
 
The results of the media alert support the assumption that professional 
initiatives in a medical journal may alter established prescription 
practice.  
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6.7 Paper 7. 
 
The use of antipsychotic and anticholinergic antiparkinson drugs in 
Norway after the withdrawal of orphenadrine 
 
Pål Gjerden, Lars Slørdal, Jørgen G. Bramness 
 
British Journal of Clinical Pharmacology 2009; 68(2): 238-242 
 
Extrapyramidal side-effects induced by antipsychotic drugs are treated 
with dose reduction or substitution with another antipsychotic drug or by 
the addition of anticholinergic antiparkinson agents. The withdrawal of 
orphenadrine from the Norwegian market provided a possibility to 
investigate to what degree these alternative measures were taken in 
clinical practice. 
 
Data were drawn from the Norwegian Prescription Database on the sales 
of antipsychotics and one of the two anticholinergic antiparkinson agents 
marketed in 2004, orphenadrine and biperiden, to a total of 39 758 
outpatients. These patients were reinvestigated in 2007. The 
consequences of the withdrawal of orphenadrine from the Norwegian 
market in 2005 regarding dosing, switching and cessation of 
antipsychotics and use of anticholinergics were assessed for orphenadrine 
users compared with biperiden users. 
 
Of the patients originally using orphenadrine, 28.4% stopped using the 
drug without reducing the antipsychotic dose or replacing orphenadrine 
with another anticholinergic agent. The corresponding number for 
biperiden users was 19.3%. Only 11.8% of patients switched to another 
antipsychotic drug, but they used significantly lower antipsychotic doses 
than those who stayed on the same drug. 
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The use of anticholinergic antiparkinson agents could be seen as 
superfluous for at least one-third of the patients. 
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7 Discussion 
 
7.1 Methodology 
 
This thesis employs a variety of scientific methods. Four of the 
papers are pharmacoepidemiological studies. 
Pharmacoepidemiology is the study of the use of and the effects 
of drugs in large numbers of people (26). It is a relatively new 
applied field and from the beginning has primarily concerned 
itself with the study of adverse drug effects, in particular drug 
effects that are uncommon, not dose-related and unpredictable. 
Preclinical toxicity testing has been mandatory for medicinal 
drugs since the 1938 Food, Drug, and Cosmetic Act was passed in 
the US. Drug surveillance programs were developed in the 1950s 
but it was the “Thalidomide disaster” of the early 1960s that 
demonstrated that epidemiological methods could make 
significant contributions to the study of drug effects in humans. 
The teratogenicity of thalidomide was only revealed a number of 
years after the compound had been introduced as a harmless drug 
for treating insomnia and morning sickness in pregnant women. 
 
Premarketing studies of drug effects are limited in size and time, 
usually include homogenous groups of subjects, exclude 
important subgroups and are most often compared to placebo 
instead of the best available drugs for the same indication. 
Postmarketing pharmacoepidemiological studies are much larger, 
include patients not studied prior to marketing, include patients 
using other drugs, can discover uncommon or delayed effects and 
can assess much larger numbers of drugs.  
 
The Norwegian Prescription Database contains information on all 
drugs filled by individual patients living outside institutions in 
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Norway from 1 January 2004, covering the entire population of 
4.6 million inhabitants. The magnitude and completeness of this 
database makes it rather unique.  
 
The remaining three studies employ other methods. The literature 
review of orphenadrine in Paper 4 seems to be the first of its kind 
since 1982 (27). Several highly relevant papers dealing with 
orphenadrine have been published in non-indexed, non-English 
journals, including Dutch periodicals. This may partly explain 
why orphenadrine has been on the market world-wide for so long, 
and still is.  
 
7.2 Main results 
 
This thesis reports on the use as well as the qualities of 
anticholinergic agents. In some aspects it also transcends 
anticholinergic agents by evaluating antipsychotic agents, both as 
a class and as individual drugs.  
 
The thesis reports a number of strictly epidemiological findings 
concerning the users of anticholinergic antiparkinson agents and 
the selection of anticholinergic agents following warnings in a 
medical journal and restrictions in availability. It argues that at 
least one third of the use of anticholinergics is superfluous. 
 
In addition, the thesis seems to allow drawing certain conclusions 
regarding the innate qualities of anticholinergic agents: The risk 
of abuse of anticholinergics is low. Toxicity and mortality differs 
significantly within this class of drugs and orphenadrine stands 
out as a particularly toxic drug.  
 
The most original contributions made by this thesis are the results 
that transcend anticholinergic agents: The liability of specific 
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antipsychotic agents to cause EPS can be compared by the 
concomitant use of anticholinergics. The concurrent use of 
anticholinergics demonstrates that the classification of 
antipsychotic agents as typical first-generation or atypical second-
generation does not correspond with the alleged criteria for this 
classification. Concomitant use of anticholinergics in long-term 
antipsychotic medication may even be a contributory factor for 
the evaluation of the efficacy of specific antipsychotic agents, not 
only their effectiveness. 
 
The disproportionately high mortality confined to long-term 
prescription of haloperidol must be considered an important but 
chance finding, a finding supported by other studies but not 
explained. 
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 7   Conclusions  
 
 
In Norway in 2004 an overwhelming majority of the anticholinergic 
users were patients concomitantly using antipsychotic agents. We 
assumed that the reason for this use was EPS induced by antipsychotic 
drugs and the presumed alleviation of these symptoms by anticholinergic 
drugs.  
 
We also found that the use of anticholinergic agents was not very skewed 
and we did not find any other indications of abuse of anticholinergic 
agents.  
 
The lack of skewedness, together with the narrow indication for the use 
of these drugs, instigated the possibility of using the prevalence of 
concomitantly prescribed anticholinergics as a proxy for the prevalence 
of the respective antipsychotic agents’ liability to cause EPS. The exact 
prevalence could not be estimated, but the relative risk of each 
antipsychotic drug to cause EPS compared to the corresponding risk of 
other antipsychotics should be fairly accurately assessed. 
 
The prevalence of drug-induced parkinsonism varied significantly, but 
largely independently of the classification of an antipsychotic drug as 
either FGA or SGA. 
 
Long-term prescription persistence of a specific antipsychotic agent can 
be a proxy for its effectiveness. Concomitant use of anticholinergic 
antiparkinson drugs can be a proxy for antipsychotic induced EPS. 
Comparing long-term use of both antipsychotic and anticholinergic 
agents may indirectly be used in the evaluation of the efficacy of 
antipsychotic agents.  
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The literature clearly demonstrates a difference between the various 
anticholinergics regarding toxicity and mortality. When we 
retrospectively studied a series of fatality cases the finding was the same, 
namely that orphenadrine had been causing a disproportionately high 
number of deaths compared to the other anticholinergic agents. 
 
When we warned against the use of orphenadrine in Norway, the use 
declined significantly compared to Sweden and Denmark. 
 
When orphenadrine was withdrawn from the market and the patients had 
to stop using this drug, one third of them managed to do so without 
reducing antipsychotic dosage, switching antipsychotic agent or using 
another anticholinergic agent. At least one third of the patients using 
anticholinergic agents probably did not need them. 
 
A surprise finding was that every fourth patient being prescribed 
haloperidol was dead in three years. Haloperidol was associated with a 
mortality three times that of any of the other antipsychotic agents 
included in the study. 
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Errata
Paper 6 
The  lower panel in Figure 1 in Paper 6 (Effect of warnings in a medical 
journal on the use of orphenadrine), does not differentiate Denmark from 
Sweden. The curve for Denmark starts slightly below the curve for 
Sweden and ends higher. 
Paper 3 
In the published version of Paper 3 (Prescription persistence and safety of 
antipsychotic medication: a national registry-based 3-year follow-up) the 
following changes have been made compared to the original manuscript 
(the original version in square brackets): 
Table 2: ”Risk of death by the end of 2007 for patients using 
antipsychotic drugs in 2004, expressed as odds ratio (OR) and 95% 
confidence interval (CI)…” [Odds ratio (OR) for patients using 
antipsychotic drugs in 2004 of having died at the end of 2007.] 
Table 3: ”Likelihood that patients using antipsychotic drugs in 2004 
would remain with the same antipsychotic drug in 2007, expressed as 
odds ratio (OR) and 95% confidence interval (CI)…” [Odds ratio (OR) 
for patients using antipsychotic drugs in 2004 of staying with the same 
antipsychotic drug in 2007.] 
Introduction: ”…, all antipsychotic agents would be evaluated in the 
same way.” […, this would require that all antipsychotic agents were 
evaluated in the same way.] 
Material and methods: ”…, use of a drug primarily in institutions might 
indicate that psychiatrists prefer it as treatment for the most severely…” 
[…, drugs which were primarily used in institutions might indicate which 
drugs the psychiatrists preferred as treatment for the most severely…] 
”comprised patients” [was constituted by patients] 
Results: ”the group using chlorprotixene” [the chlorprotixene using 
group]
”…, use of anticholinergics and use of specific antipsychotics ” […, if 
the patient used anticholinergics and the use of specific antipsychotics] 
Discussion: ”prior to” [preceeding] 
A few misspellings have been corrected. 
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